EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)
Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 monthsNo included studies addressed direct and indirect costs to participants and health services (review-wide gap).0 studiesNo studies found